Cellectis S.A.(CLLS)Earnings, Financials & Key Ratios
CLLS•NASDAQ
$3.95
$287M mkt cap·Price updated May 6, 2026
AboutCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Show more
- Revenue$42M+5397.5%
- EBITDA-$40M+49.6%
- Net Income-$37M+63.6%
- EPS (Diluted)-0.41+76.8%
- Gross Margin77.88%+108.8%
- EBITDA Margin-95.67%+99.1%
- Operating Margin-143.48%+98.9%
- Net Margin-88.57%+99.3%
- ROE-34.08%+64.5%
- ROIC-79.56%+21.0%
- Debt/Equity0.70-30.5%
- Interest Coverage-7.99+56.4%
CLLS Key Insights
Cellectis S.A. (CLLS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 47.0% free cash flow margin
- ✓Strong 5Y sales CAGR of 22.3%
✗Weaknesses
- ✗Shares diluted 58.9% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CLLS Price & Volume
Cellectis S.A. (CLLS) stock price & volume — 10-year historical chart
Loading chart...
CLLS Growth Metrics
Cellectis S.A. (CLLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.67%
5 Years22.27%
3 Years11%
TTM158.91%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM58.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM66.37%
Return on Capital
10 Years-28.26%
5 Years-30.65%
3 Years-38.46%
Last Year-30.05%
CLLS Recent Earnings
Cellectis S.A. (CLLS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Mar 19, 2026EPS
$0.26
Est $0.20
-27.9%
Revenue
$12M
Est $13M
-8.9%
Q4 2025
Nov 7, 2025EPS
$0.01
Est $0.10
+110.0%
Revenue
$35M
Est $10M
+242.4%
Q3 2025
Aug 4, 2025EPS
$0.24
Est $0.10
-140.0%
Revenue
$17M
Est $8M
+106.0%
Q2 2025
May 12, 2025EPS
$0.18
Est $0.19
+5.3%
Revenue
$11M
Est $13M
-16.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 19, 2026 | $0.26vs $0.20-27.9% | $12Mvs $13M-8.9% |
| Q4 2025 | Nov 7, 2025 | $0.01vs $0.10+110.0% | $35Mvs $10M+242.4% |
| Q3 2025 | Aug 4, 2025 | $0.24vs $0.10-140.0% | $17Mvs $8M+106.0% |
| Q2 2025 | May 12, 2025 | $0.18vs $0.19+5.3% | $11Mvs $13M-16.2% |
Based on last 12 quarters of dataView full earnings history →
CLLS Peer Comparison
Cellectis S.A. (CLLS) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 ALLO | 529.95M | 2.31 | -2.66 | -100% | -57.07% | 0.26 | ||
 SANA | 954.64M | 3.64 | -3.14 | -120.02% | 0.38 | |||
 CABA | 381.44M | 3.73 | -2.27 | -121.73% | 0.24 |
Compare CLLS vs Peers
Cellectis S.A. (CLLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLLS Income Statement
Cellectis S.A. (CLLS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 42.58M | 25.19M | 12.73M | 15.19M | 51.06M | 30.35M | 19.17M | 755K | 41.51M | 75.27M |
| Revenue Growth % | -22.63% | -40.85% | -49.46% | 19.32% | 236.12% | -40.56% | -36.83% | -96.06% | 5397.48% | 158.91% |
| Cost of Goods Sold | 1.69M | 2.62M | 2.74M | 11.39M | 1.95M | 1.84M | 8.48M | 7.42M | 9.18M | 9.31M |
| COGS % of Revenue | 3.96% | 10.4% | 21.51% | 75% | 3.82% | 6.08% | 44.25% | 982.65% | 22.12% | - |
| Gross Profit | 40.9M▲ 0% | 22.57M▼ 44.8% | 9.99M▼ 55.7% | 3.8M▼ 62.0% | 49.11M▲ 1192.9% | 28.5M▼ 42.0% | 10.69M▼ 62.5% | -6.66M▼ 162.4% | 32.32M▲ 585.1% | 65.96M▲ 0% |
| Gross Margin % | 96.04% | 89.6% | 78.49% | 25% | 96.18% | 93.92% | 55.75% | -882.65% | 77.88% | 87.63% |
| Gross Profit Growth % | -21.86% | -44.82% | -55.72% | -61.99% | 1192.94% | -41.96% | -62.5% | -162.36% | 585.05% | - |
| Operating Expenses | 104.86M | 115.22M | 115.08M | 127.35M | 91.42M | 131.98M | 100.35M | 90.64M | 91.88M | 92.36M |
| OpEx % of Revenue | 246.23% | 457.43% | 903.96% | 838.38% | 179.05% | 434.93% | 523.46% | 12005.03% | 221.36% | - |
| Selling, General & Admin | 41.26M | 44.75M | 47.25M | 43.02M | 22.51M | 22.88M | 8.89M | 8.12M | 8.42M | 8.04M |
| SG&A % of Revenue | 96.89% | 177.66% | 371.13% | 283.19% | 44.1% | 75.4% | 46.4% | 1075.36% | 20.29% | - |
| Research & Development | 74.56M | 79.23M | 76.57M | 92.04M | 77.05M | 117.84M | 97.5M | 87.65M | 90.54M | 89.95M |
| R&D % of Revenue | 175.1% | 314.54% | 601.42% | 605.94% | 150.91% | 388.32% | 508.59% | 11608.74% | 218.13% | - |
| Other Operating Expenses | -19.38M | -17.9M | -25.42M | -7.71M | -8.14M | -8.74M | -6.04M | -5.13M | -7.08M | -3.92M |
| Operating Income | -63.96M▲ 0% | -92.65M▼ 44.9% | -105.09M▼ 13.4% | -123.55M▼ 17.6% | -42.31M▲ 65.8% | -103.48M▼ 144.6% | -89.67M▲ 13.4% | -97.3M▼ 8.5% | -59.55M▲ 38.8% | -26.41M▲ 0% |
| Operating Margin % | -150.2% | -367.83% | -825.47% | -813.38% | -82.87% | -341% | -467.72% | -12887.68% | -143.48% | -35.08% |
| Operating Income Growth % | -109.51% | -44.85% | -13.43% | -17.57% | 65.75% | -144.57% | 13.35% | -8.52% | 38.79% | - |
| EBITDA | -61.75M | -89.28M | -102.71M | -116.68M | -34.48M | -89.33M | -71.23M | -78.78M | -39.71M | -5.62M |
| EBITDA Margin % | -145.01% | -354.45% | -806.8% | -768.12% | -67.53% | -294.36% | -371.56% | -10434.3% | -95.67% | -7.46% |
| EBITDA Growth % | -115.75% | -44.58% | -15.05% | -13.59% | 70.45% | -159.09% | 20.26% | -10.6% | 49.6% | 90.52% |
| D&A (Non-Cash Add-back) | 2.21M | 3.37M | 2.38M | 6.88M | 7.83M | 14.16M | 18.43M | 18.52M | 19.85M | 20.79M |
| EBIT | -67.25M | -103.68M | -88.29M | -112.61M | -51.17M | -92.58M | -94.81M | -111.16M | -29.31M | -26.86M |
| Net Interest Income | -583K | 1.41M | 6.06M | 4.02M | -1.69M | -3.65M | -2.67M | -1.69M | 3.83M | 3.18M |
| Interest Income | 44.17K | 1.97M | 6.79M | 6.98M | 1.96M | 719K | 1.12M | 3.61M | 11.28M | 10.99M |
| Interest Expense | 6.31K | 560K | 723K | 2.96M | 3.65M | 4.37M | 3.79M | 5.31M | 7.45M | 7.81M |
| Other Income/Expense | 47K | -11.03M | 16.76M | 8.34M | -11.27M | 6.73M | -8.94M | -19.16M | 22.79M | -8.43M |
| Pretax Income | -63.92M▲ 0% | -103.68M▼ 62.2% | -88.33M▲ 14.8% | -115.21M▼ 30.4% | -53.58M▲ 53.5% | -96.75M▼ 80.6% | -98.6M▼ 1.9% | -116.46M▼ 18.1% | -36.76M▲ 68.4% | -34.84M▲ 0% |
| Pretax Margin % | -150.09% | -411.63% | -693.84% | -758.47% | -104.94% | -318.83% | -514.32% | -15425.7% | -88.57% | -46.28% |
| Income Tax | -1.54M | -13.2M | 0 | 0 | 0 | -3K | 87K | 371K | 0 | 514K |
| Effective Tax Rate % | 2.42% | 12.73% | 0% | 0% | 0% | 0% | -0.09% | -0.32% | 0% | -1.48% |
| Net Income | -63.92M▲ 0% | -99.37M▼ 55.5% | -78.69M▲ 20.8% | -102.09M▼ 29.7% | -81.07M▲ 20.6% | -114.2M▼ 40.9% | -106.14M▲ 7.1% | -101.06M▲ 4.8% | -36.76M▲ 63.6% | -35.35M▲ 0% |
| Net Margin % | -150.1% | -394.51% | -618.12% | -672.09% | -158.79% | -376.32% | -553.64% | -13385.3% | -88.57% | -46.97% |
| Net Income Growth % | -184.58% | -55.46% | 20.81% | -29.73% | 20.59% | -40.86% | 7.06% | 4.79% | 63.62% | 58.67% |
| Net Income (Continuing) | -67.25M | -103.68M | -88.33M | -115.21M | -53.58M | -96.75M | -98.69M | -116.83M | -36.76M | -35.35M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -43.9M | -28.36M | -15.35M | 8.39M | 0 | 0 |
| Minority Interest | 1.87M | 19.11M | 40.97M | 40.35M | 25.05M | 15.18M | 7.97M | 0 | 0 | 0 |
| EPS (Diluted) | -1.78▲ 0% | -2.78▼ 56.2% | -1.93▲ 30.6% | -2.14▼ 10.9% | -1.71▲ 20.1% | -1.93▼ 12.9% | -2.33▼ 20.7% | -1.77▲ 24.0% | -0.41▲ 76.8% | -0.35▲ 0% |
| EPS Growth % | -173.85% | -56.18% | 30.58% | -10.88% | 20.09% | -12.87% | -20.73% | 24.03% | 76.84% | 66.37% |
| EPS (Basic) | -1.81 | -2.78 | -1.93 | -2.14 | -1.71 | -1.93 | -2.33 | -1.77 | -0.41 | - |
| Diluted Shares Outstanding | 35.81M | 35.69M | 40.77M | 42.44M | 42.5M | 44.82M | 45.55M | 57.01M | 90.57M | 100.33M |
| Basic Shares Outstanding | 35.29M | 35.69M | 40.77M | 42.44M | 42.5M | 44.82M | 45.55M | 57.01M | 90.57M | 100.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLLS Balance Sheet
Cellectis S.A. (CLLS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 311.79M | 323.22M | 487.64M | 391.52M | 315.36M | 225.43M | 143.81M | 233.01M | 287.07M | 221.19M |
| Cash & Short-Term Investments | 290.5M | 296.98M | 451.89M | 360.91M | 268.24M | 186.13M | 97.7M | 203.81M | 260.31M | 190.22M |
| Cash Only | 290.5M | 296.98M | 451.89M | 360.91M | 241.15M | 185.64M | 89.79M | 136.71M | 143.25M | 52.24M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 27.09M | 499K | 7.91M | 67.11M | 117.06M | 137.98M |
| Accounts Receivable | 3.63M | 4.57M | 22.07M | 15.29M | 19.19M | 31.07M | 17.57M | 23.13M | 23.04M | 26.41M |
| Days Sales Outstanding | 31.09 | 66.15 | 632.66 | 367.48 | 137.22 | 373.74 | 334.59 | 11.18K | 202.59 | 126.5 |
| Inventory | 117.79K | 250K | 275K | 2.9M | 1.61M | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 25.47 | 34.83 | 36.65 | 92.82 | 300.46 | - | - | - | - | - |
| Other Current Assets | 363K | 2.99M | 2.42M | 594K | 12.21M | 50K | 22.31M | 345K | 298K | 4.55M |
| Total Non-Current Assets | 18.89M | 9.66M | 13.2M | 75.95M | 154.11M | 156.65M | 117.41M | 101.27M | 96.48M | 121.85M |
| Property, Plant & Equipment | 16.86M | 7.23M | 10.04M | 69.32M | 145.52M | 148.27M | 107.9M | 92.74M | 75.86M | 66.71M |
| Fixed Asset Turnover | 2.53x | 3.49x | 1.27x | 0.22x | 0.35x | 0.20x | 0.18x | 0.01x | 0.55x | 1.05x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.34M | 1.43M | 1.27M | 1.11M | 1.58M | 1.85M | 718K | 672K | 1.11M | 845K |
| Long-Term Investments | 689.92K | 1M | 1.89M | 5.52M | 7.01M | 6.52M | 8.79M | 7.85M | 7.52M | 13.32M |
| Other Non-Current Assets | 0 | 102K | -1K | 5.52M | -1K | 3K | 0 | -1K | 11.6M | 130.41M |
| Total Assets | 330.68M▲ 0% | 332.88M▲ 0.7% | 500.84M▲ 50.5% | 467.47M▼ 6.7% | 469.47M▲ 0.4% | 382.08M▼ 18.6% | 261.22M▼ 31.6% | 334.27M▲ 28.0% | 383.54M▲ 14.7% | 343.05M▲ 0% |
| Asset Turnover | 0.13x | 0.08x | 0.03x | 0.03x | 0.11x | 0.08x | 0.07x | 0.00x | 0.11x | 0.21x |
| Asset Growth % | -11.32% | 0.67% | 50.46% | -6.66% | 0.43% | -18.62% | -31.63% | 27.97% | 14.74% | -8.95% |
| Total Current Liabilities | 56.04M | 43.53M | 46.87M | 62.6M | 52.02M | 49.35M | 62.99M | 155.14M | 166.27M | 148.58M |
| Accounts Payable | 9.72M | 9.46M | 15.88M | 29.26M | 24.61M | 23.76M | 21.46M | 19.07M | 18.66M | 16.09M |
| Days Payables Outstanding | 2.1K | 1.32K | 2.12K | 937.62 | 4.6K | 4.7K | 923.08 | 938.16 | 741.93 | 680.95 |
| Short-Term Debt | 1.69M | 0 | 0 | 0 | 0 | 2.25M | 4.97M | 5.16M | 4.84M | 5.45M |
| Deferred Revenue (Current) | 38.84M | 26.06M | 20.75M | 20.03M | 452K | 301K | 59K | 110.33M | 112.16M | 338.84M |
| Other Current Liabilities | 1.46M | 2.02M | 2.86M | 4.95M | 7.21M | 2.16M | 16.16M | 2.72M | 13.37M | 118.7M |
| Current Ratio | 5.56x | 7.42x | 10.40x | 6.25x | 6.06x | 4.57x | 2.28x | 1.50x | 1.73x | 1.73x |
| Quick Ratio | 5.56x | 7.42x | 10.40x | 6.21x | 6.03x | 4.57x | 2.28x | 1.50x | 1.73x | 1.73x |
| Cash Conversion Cycle | -2.05K | -1.22K | -1.45K | -477.32 | -4.17K | - | - | - | - | -554.45 |
| Total Non-Current Liabilities | 588.95K | 3.44M | 3.7M | 49.4M | 108.61M | 96.25M | 72.28M | 94.43M | 95.25M | 93.99M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 24.22M | 18.77M | 13.57M | 28.44M | 43.99M | 49.74M |
| Capital Lease Obligations | 30K | 13K | 1.02M | 46.54M | 75.76M | 71.53M | 49.36M | 42.95M | 34.24M | 128.9M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 158K | 0 | 0 |
| Other Non-Current Liabilities | 560K | 3.43M | 2.68M | 2.85M | 8.63M | 5.96M | 9.35M | 22.88M | 17.02M | 32.4M |
| Total Liabilities | 56.63M | 46.98M | 50.57M | 112M | 160.63M | 145.6M | 135.28M | 249.57M | 252.51M | 242.57M |
| Total Debt | 1.76M | 34K | 1.35M | 47.61M | 106.68M | 100.87M | 75.77M | 85.06M | 91.46M | 92.78M |
| Net Debt | -288.74M | -296.95M | -450.54M | -313.3M | -134.47M | -84.77M | -14.02M | -51.65M | -51.79M | 40.53M |
| Debt / Equity | 0.01x | 0.00x | 0.00x | 0.13x | 0.35x | 0.43x | 0.60x | 1.00x | 0.70x | 0.70x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -16.52x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -7.22x |
| Interest Coverage | -10136.33x | -165.45x | -145.35x | -41.75x | -11.58x | -23.69x | -23.68x | -18.33x | -7.99x | -3.44x |
| Total Equity | 274.05M▲ 0% | 285.9M▲ 4.3% | 450.27M▲ 57.5% | 355.47M▼ 21.1% | 308.85M▼ 13.1% | 236.47M▼ 23.4% | 125.94M▼ 46.7% | 84.69M▼ 32.8% | 131.03M▲ 54.7% | 100.48M▲ 0% |
| Equity Growth % | -4.92% | 4.33% | 57.49% | -21.05% | -13.12% | -23.43% | -46.74% | -32.75% | 54.71% | 26% |
| Book Value per Share | 7.65 | 8.01 | 11.04 | 8.38 | 7.27 | 5.28 | 2.76 | 1.49 | 1.45 | 1.00 |
| Total Shareholders' Equity | 272.18M | 266.79M | 409.3M | 315.12M | 283.8M | 221.29M | 117.97M | 84.69M | 131.03M | 100.48M |
| Common Stock | 1.86M | 2.37M | 2.77M | 2.77M | 2.79M | 2.94M | 2.96M | 4.37M | 5.89M | 5.9M |
| Retained Earnings | -229.77M | -351.3M | -405.32M | -508.48M | -587.03M | -698.33M | -439.5M | -405.77M | -329.61M | -307.86M |
| Treasury Stock | -416K | -297K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.63M | 1.98M | -16.67M | -22.64M | -4.09M | -18.02M | -28.61M | -36.69M | -39.54M | -32.73M |
| Minority Interest | 1.87M | 19.11M | 40.97M | 40.35M | 25.05M | 15.18M | 7.97M | 0 | 0 | 0 |
CLLS Cash Flow Statement
Cellectis S.A. (CLLS) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -31.09M | -52.33M | -68.14M | -69.14M | -80.26M | -104.56M | -87.44M | -24.75M | 22.1M | 22.1M |
| Operating CF Margin % | -73% | -207.75% | -535.21% | -455.18% | -157.2% | -344.57% | -456.13% | -3277.62% | 53.25% | - |
| Operating CF Growth % | -978.69% | -68.32% | -30.21% | -1.47% | -16.08% | -30.28% | 16.37% | 71.7% | 189.32% | -120.43% |
| Net Income | -63.92M | -103.68M | -88.33M | -115.21M | -53.58M | -96.75M | -98.69M | -116.83M | -36.7M | -35.35M |
| Depreciation & Amortization | 2.1M | 3.37M | 2.38M | 6.88M | 7.83M | 14.16M | 18.43M | 18.52M | 19.84M | 20.79M |
| Stock-Based Compensation | 55.71M | 50.42M | 37.22M | 26.88M | 10.03M | 11.49M | 6.04M | 5.23M | 0 | 3.14M |
| Deferred Taxes | 1.32M | 4.32M | 6.46M | 0 | 0 | 0 | 87K | 371K | 0 | -25K |
| Other Non-Cash Items | -1.4M | 11.04M | -16.76M | 661K | -27.22M | -21.16M | -7.6M | 71.95M | -14.61M | -1.09M |
| Working Capital Changes | -24.9M | -17.79M | -9.1M | 11.65M | -17.32M | -12.3M | -5.72M | -3.99M | 53.57M | -16.55M |
| Change in Receivables | -947.58K | -549K | -3.7M | 4.68M | -3.23M | -12.44M | -8.99M | 2.25M | -6.72M | 2.04M |
| Change in Inventory | 47.33K | -109K | -37K | -2.63M | 100K | 215K | 0 | 0 | 0 | 0 |
| Change in Payables | -4.17M | -335K | 9.37M | 9.63M | 5.69M | 177K | 3.25M | -6.3M | 2.05M | -3.31M |
| Cash from Investing | -50.5M | 1.78M | 35.62M | -35.87M | -54.34M | 7.28M | -2.76M | -15.51M | -102.63M | -68.6M |
| Capital Expenditures | -13.34M | -2.66M | -4.89M | -12.91M | -44.08M | -18.54M | -2.43M | -1.07M | -3.84M | -2.43M |
| CapEx % of Revenue | 31.32% | 10.54% | 38.38% | 85.01% | 86.33% | 61.11% | 12.68% | 142.12% | 9.24% | - |
| Acquisitions | -298.68K | 7.16M | 1.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 321.82K | 7.16M | 1.26M | 369K | -13.15M | 10.96M | -456K | -14.44M | 0 | -3.46M |
| Cash from Financing | 460.64K | 41.27M | 236.49M | -3.86M | 27.32M | 47.52M | 1.15M | 82.86M | 89.8M | -9.7M |
| Debt Issued (Net) | -91K | -41K | -127K | -3.39M | 19.43M | -10.64M | -6.6M | 24.56M | 18.17M | -8.98M |
| Equity Issued (Net) | 576K | 1000K | 1000K | 0 | 1000K | 1000K | -569K | 1000K | 1000K | -1K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -137K | 0 | 0 | -469K | 0 | 0 | -569K | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 7.77M | -469K | -1.32M | 13.53M | 8.32M | -9.63M | -11.04M | -718K |
| Net Change in Cash | -76.5M▲ 0% | 1.81M▲ 102.4% | 195.12M▲ 10668.3% | -110.98M▼ 156.9% | -99.37M▲ 10.5% | -55.51M▲ 44.1% | -92.42M▼ 66.5% | 43.49M▲ 147.1% | 6.54M▼ 85.0% | -106.84M▲ 0% |
| Free Cash Flow | -44.42M▲ 0% | -54.98M▼ 23.8% | -73.02M▼ 32.8% | -82.1M▼ 12.4% | -124.68M▼ 51.9% | -123.12M▲ 1.3% | -89.89M▲ 27.0% | -25.82M▲ 71.3% | 19.52M▲ 175.6% | -32.71M▲ 0% |
| FCF Margin % | -104.32% | -218.29% | -573.58% | -540.49% | -244.21% | -405.71% | -468.86% | -3419.74% | 47.04% | -43.46% |
| FCF Growth % | -6113.1% | -23.77% | -32.81% | -12.43% | -51.87% | 1.26% | 26.99% | 71.28% | 175.62% | -154.18% |
| FCF per Share | -1.24 | -1.54 | -1.79 | -1.93 | -2.93 | -2.75 | -1.97 | -0.45 | 0.22 | 0.22 |
| FCF Conversion (FCF/Net Income) | 0.49x | 0.53x | 0.87x | 0.68x | 0.99x | 0.92x | 0.82x | 0.24x | -0.60x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLLS Key Ratios
Cellectis S.A. (CLLS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -22.74% | -35.49% | -21.38% | -25.34% | -24.41% | -41.88% | -58.57% | -95.96% | -34.08% | -31.79% |
| Return on Invested Capital (ROIC) | - | - | - | -442.28% | -29.31% | -47.6% | -51.02% | -100.68% | -79.56% | -79.56% |
| Gross Margin | 96.04% | 89.6% | 78.49% | 25% | 96.18% | 93.92% | 55.75% | -882.65% | 77.88% | 87.63% |
| Net Margin | -150.1% | -394.51% | -618.12% | -672.09% | -158.79% | -376.32% | -553.64% | -13385.3% | -88.57% | -46.97% |
| Debt / Equity | 0.01x | 0.00x | 0.00x | 0.13x | 0.35x | 0.43x | 0.60x | 1.00x | 0.70x | 0.70x |
| Interest Coverage | -10136.33x | -165.45x | -145.35x | -41.75x | -11.58x | -23.69x | -23.68x | -18.33x | -7.99x | -3.44x |
| FCF Conversion | 0.49x | 0.53x | 0.87x | 0.68x | 0.99x | 0.92x | 0.82x | 0.24x | -0.60x | 0.93x |
| Revenue Growth | -22.63% | -40.85% | -49.46% | 19.32% | 236.12% | -40.56% | -36.83% | -96.06% | 5397.48% | 158.91% |
CLLS Frequently Asked Questions
Cellectis S.A. (CLLS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cellectis S.A. (CLLS) reported $75.3M in revenue for fiscal year 2024. This represents a 1735% increase from $4.1M in 2007.
Cellectis S.A. (CLLS) grew revenue by 5397.5% over the past year. This is strong growth.
Cellectis S.A. (CLLS) reported a net loss of $35.4M for fiscal year 2024.
Dividend & Returns
Cellectis S.A. (CLLS) has a return on equity (ROE) of -34.1%. Negative ROE indicates the company is unprofitable.
Cellectis S.A. (CLLS) had negative free cash flow of $32.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More CLLS
Cellectis S.A. (CLLS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates